Yes agreed Mozz 100%, Bene are manufacturing experts and have been doing this for 70 odd years. It’s their wheel house.
They take very little risk but if the drug gets approved they sit back and clip the ticket at what would be significant margins. Plus what they would charge PAR to supply the drug.
When you clip the ticket on multiple drugs to multiple companies, for multiple indications in multiple countries this all adds up to a great business. It’s simply their business and not clinical trials and sales forces etc. Also scaling manufacturing to meet demand would be their specialty allowing them to be so successful for so long.
They would be as happy to have us as partners with our prospects as we are to have them with their FDA approved supply. A genuine win / win all going well.
MADE IN GERMANY, page-15
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $69.17M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.0¢ | $148.6K | 756.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 190014 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 42970 | 10 |
View Market Depth
| Last trade - 15.31pm 01/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |